Frequency and prognostic significance of pericardial effusion in primary pulmonary hypertension. PPH Study Group. Primary pulmonary hypertension

A L Hinderliter; P W Willis 4th; W Long; W R Clarke; D Ralph; E J Caldwell; W Williams; N A Ettinger; N S Hill; W R Summer; B de Biosblanc; G Koch; S Li; L M Clayton; M M Jöbsis; J W Crow

doi:10.1016/s0002-9149(99)00342-2

Frequency and prognostic significance of pericardial effusion in primary pulmonary hypertension. PPH Study Group. Primary pulmonary hypertension

Am J Cardiol. 1999 Aug 15;84(4):481-4, A10. doi: 10.1016/s0002-9149(99)00342-2.

Authors

A L Hinderliter¹, P W Willis 4th, W Long, W R Clarke, D Ralph, E J Caldwell, W Williams, N A Ettinger, N S Hill, W R Summer, B de Biosblanc, G Koch, S Li, L M Clayton, M M Jöbsis, J W Crow

Affiliation

¹ Department of Medicine, University of North Carolina, Chapel Hill 27599-7075, USA.

PMID: 10468096
DOI: 10.1016/s0002-9149(99)00342-2

Abstract

Pericardial effusion was noted in 43 of 79 patients (54%) with severe primary pulmonary hypertension. Larger effusion was associated with hemodynamic and echocardiographic evidence of right heart failure, impaired exercise tolerance, and a poor 1-year prognosis.

Publication types

Clinical Trial
Comparative Study
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

MeSH terms

Adult
Antihypertensive Agents / administration & dosage
Antihypertensive Agents / therapeutic use
Echocardiography, Doppler
Epoprostenol / administration & dosage
Epoprostenol / therapeutic use
Female
Follow-Up Studies
Humans
Hypertension, Pulmonary / complications*
Hypertension, Pulmonary / diagnosis
Hypertension, Pulmonary / drug therapy
Infusions, Intravenous
Male
Pericardial Effusion / diagnosis
Pericardial Effusion / epidemiology*
Pericardial Effusion / etiology
Prevalence
Prognosis
Pulmonary Wedge Pressure
Survival Rate

Substances

Antihypertensive Agents
Epoprostenol